Skip to main content
. Author manuscript; available in PMC: 2008 Nov 24.
Published in final edited form as: Psychopharmacology (Berl). 2008 May 29;199(2):265–273. doi: 10.1007/s00213-008-1190-z

Figure 5.

Figure 5

The CB1-selective antagonist rimonabant (RIM) reverses both high- (3 mg/kg) and low-dosage (0.3 mg/kg) effects of the cannabinoid agonist WIN55212-2. Densities of anti-c-Fos reactive cells within HVC (panels A and C) or RA (panels B and D) following high- (panels A and B) and low-WIN dosage treatments (panels C and D) are shown as a fraction of vehicle controls (VEH). Significant differences from VEH groups following 2-way ANOVA and Student-Neuman-Keuls post-tests are indicated by asterisks (*p < 0.05). Differences from WIN treatments (3 or 0.3 mg/kg WIN) are indicated by single daggers (†p < 0.05). The double-dagger in panel B indicates a significant difference from the combined treatment of 6 mg/kg rimonabant and 3 mg/kg WIN55212-2 (‡p < 0.05).